Table 3. Comparison of frequencies of qualitative indicators with OS and PFS in mCRC patients with synchronous and metachronous metastasis.

Clinicopathological parameters	N	Mean OS (months. CI 95%)	Log-rank	p-value	Mean PFS (months. CI 95%)	Log-rank	p-value
Gender
Male	32	17.0 (13.4–20.6)	2.479	0.115	9.0 (7.7–10.3)	0.471	0.493
Female	28	16.0 (12.8–19.2)			8.0 (5.4–10.3)
Age range
≤65 years	22	17.0 (13.8–20.2)	0.012	0.914	8.0 (5.2–10.8)	0.049	0.825
>65 years	38	17.0 (14.0–20.0)			9.0 (7.8–10.2)
Type (Localized/Metastasized)
Synchronous	31	13.5 (9.7–17.3)	8.963	0.003	6.0 (3.3–8.7)	11.395	0.001
Metachronous	29	20.0 (13.7–26.3)			11.0 (10.0–12.0)
Location of tumor
Left-sided	25	20.0 (16.8–23.2)	0.314	0.575	11.0 (9.0–13.0)	4.664	0.031
Right-sided	35	14.5 (11.6–17.4)			8.0 (5.5–10.5)
Stage
I	5	-	11.592	0.009	11.0 (8.9–13.1)	11.591	0.009
II	6	17.0 (13.6–20.4)			11.0 (8.7–13.3)
III	18	19.0 (14.8–23.2)			10.0 (5.8–14.2)
IV	31	14.0 (10.4–17.6)			6.0 (3.3–8.7)
Depth of invasion
T2	7	-	6.536	0.038	11.0 (9.2–12.2)	2.947	0.229
T3	42	17.0 (14.6–19.4)			9.0 (8.0–10.0)
T4	11	11.5 (8.3–14.7)			4.0 (1.8–6.2)
Lymph node metastasis
N0	11	23.0 (18.0–28.0)	27.584	<0.0001	11.0 (10.2–11.8)	18.338	<0.0001
N1	36	19.0 (15.5–22.5)			9.0 (7.5–10.5)
N2	13	11.0 (7.9–14.1)			4.0 (1.7–6.3)
Histology
Adenocarcinoma	50	17.0 (14.7–19.3)	1.668	0.434	9.0 (7.3–10.7)	0.878	0.645
Mucinous carcinoma	8	13.0 (10.7–15.3)			7.0 (4.2–9.8)
Signet-ring cell carcinoma	1	-			11.0
Grade of differentiation
Moderate	24	21.5 (16.7–26.3)	6.378	0.012	11.0 (8.6–13.4)	8.307	0.004
High	36	14.5 (11.6–17.4)			8.0 (6.5–9.5)
Therapy
Sole surgical resection	1	6.0	13.175	<0.0001	4.0	2.533	0.282
+ chemotherapy	55	17.0 (14.2–19.8)			9.0 (7.8–10.2)
+ chemoradiation	4	20.0 (5.3–34.7)			11.0 (2.7–19.3)
Resection
R0	57	17.0 (14.5–19.5)	0.571	0.450	9.0 (7.7–10.3)	1.411	0.235
R1+R2	3	13.5 (11.1–15.9)			8.0 (6.4–9.6)
E-cadherin in primary tumor
Low	12	12.0 (9.5–14.5)	0.019	0.889	4.0 (2.6–5.4)	1.405	0.236
High	14	13.0 (9.4–17.6)			8.0 (6.2–9.8)
E-cadherin in metastasis
Low	12	19.0 (13.9–24.1)	12.291	<0.0001	11.0 (6.0–16.0)	8.458	0.004
High	16	11.0 (9.5–12.5)			6.0 (4.7–7.3)
Musashi 2 in primary tumor
Low	21	20.0 (15.5–24.5)	2.849	0.091	11.5 (9.6–13.4)	12.627	<0.0001
High	39	14.0 (11.3–16.7)			8.0 (6.3–9.7)
Musashi 2 in metastasis
Low	22	24.5 (20.8–28.2)	12.555	<0.0001	11.0 (8.7–13.3)	13.481	<0.0001
High	38	13.0 (10.7–15.2)			7.0 (5.0–9.0)

The Kaplan-Meier method was used to construct survival curves, as well as to calculate the median of survival. Differences between groups were established using a log-rank test.